Matthew J. Wong

1.1k citations

12 papers · 598 indexed · h-index 8

Hematology top 5%
- Chronic Myeloid Leukemia Treatments 7
- Acute Myeloid Leukemia Research 1
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 6
Rheumatology top 10%
- Eosinophilic Disorders and Syndromes 3
Oncology
- Bone health and treatments 1
Molecular Biology
Organic Chemistry
- Click Chemistry and Applications 2
Ecology, Evolution, Behavior and Systematics
- Fungal Plant Pathogen Control 1
Radiology, Nuclear Medicine and Imaging
- Radiopharmaceutical Chemistry and Applications 1

Co-authors: Victor M. Rivera Joseph M. Gozgit Tim Clackson Scott Wardwell William C. Shakespeare Narayana I. Narasimhan Frank Wang Qurish K. Mohemmad
Cited by: Hematology Genetics Rheumatology
Journals: Proceedings of the National Academy of Sciences (1 paper)SHILAP Revista de lepidopterología (1 paper)Blood (3 papers)
Partner nations: United States Australia Canada

In The Last Decade

Matthew J. Wong

12 papers receiving 591 citations

Peers

Countries citing papers authored by Matthew J. Wong

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Wong more than expected).

Fields of papers citing papers by Matthew J. Wong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Wong. The network helps show where Matthew J. Wong may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matthew J. Wong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew J. Wong Line = papers co-authored together Matthew J. Wong links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work
1	Design of an Eta-Phase Precipitation-Hardenable Nickel-Based Alloy with the Potential for Improved Creep Strength Above 1023 K (750 °C) Metallurgical and Materials Transactions A ·Matthew J. Wong,Paul G. Sanders,John Shingledecker,C.L. White	2015	24
2	Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models Molecular Cancer Therapeutics ·Joseph M. Gozgit,Matthew J. Wong,Lauren Moran,Scott Wardwell,Qurish K. Mohemmad,Narayana I. Narasimhan,William C. Shakespeare,Frank Wang,Tim Clackson,Victor M. Rivera	2012	273
3	Abstract 853: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFRα/β and FGFR1 Cancer Research ·Joseph M. Gozgit,Matthew J. Wong,Xiaotian Zhu,Tim Clackson,Victor M. Rivera	2012	2
4	Optimal management of bone metastases in breast cancer patients Breast Cancer Targets and Therapy ·Matthew J. Wong,Pavlakis	2011	37
5	Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies Molecular Cancer Therapeutics ·Joseph M. Gozgit,Matthew J. Wong,Scott Wardwell,Jeffrey Tyner,Marc Loriaux,Qurish K. Mohemmad,Narayana I. Narasimhan,William C. Shakespeare,Frank Wang,Brian Druker,Tim Clackson,Victor M. Rivera	2011	110
6	Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant SHILAP Revista de lepidopterología ·Amir Steinberg,Rina Kansal,Matthew J. Wong,Angela M. Lopez,Stephen Lim,Jean Lopategui,Michael Lill	2011	9
7	SGX393 inhibits the CML mutant Bcr-Abl ^T315I and preempts in vitro resistance when combined with nilotinib or dasatinib Proceedings of the National Academy of Sciences ·Thomas O’Hare,Christopher A. Eide,Jeffrey Tyner,Amie S. Corbin,Matthew J. Wong,Sean G. Buchanan,Kevin R. Holme,Katayoun A. Jessen,Crystal M. Tang,H.A. Lewis,Richard Romero,S.K. Burley,Michael W. Deininger	2008	59
8	Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib Leukemia ·Daniel W. Sherbenou,Matthew J. Wong,Adil Humayun,Laura McGreevey,Patina M. Harrell,Rui Yang,Michael J. Mauro,Michael C. Heinrich,Richard D. Press,Brian Druker,Michael W. Deininger	2007	61
9	SGX70393 Inhibits Bcr-AblT315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib. Blood ·Thomas O’Hare,Christopher A. Eide,Jeffrey Tyner,Amie S. Corbin,Matthew J. Wong,Sean G. Buchanan,Kevin R. Holme,Katayoun A. Jessen,Crystal M. Tang,H.A. Lewis,Richard Romero,S.K. Burley,Michael W. Deininger	2007	3
10	Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393. Blood ·Thomas O’Hare,Christopher A. Eide,Jeffrey Tyner,Matthew J. Wong,Caitlyn Smith,Amie S. Corbin,Sean G. Buchanan,Katayoun A. Jessen,Crystal M. Tang,Kevin R. Holme,S.K. Burley,Michael W. Deininger	2006	9
11	In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse. Blood ·Daniel W. Sherbenou,Matthew J. Wong,Adil Humayun,Laura McGreevey,Rui Yang,Michael C. Heinrich,Richard D. Press,Brian Druker,Michael W. Deininger	2005	4
12	Pulmonary and neuromuscular complications of mixed connective tissue disease: a report and review of the literature. PubMed ·J B Martyn,Matthew J. Wong,Shao Hui Huang	1988	7

About Matthew J. Wong

Matthew J. Wong is a scholar working on Genetics, Hematology and Rheumatology, having authored 12 papers that have together received 598 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Eosinophilic Disorders and Syndromes (3 papers), Click Chemistry and Applications (2 papers), Fungal Plant Pathogen Control (1 paper), Acute Myeloid Leukemia Research (1 paper), Radiopharmaceutical Chemistry and Applications (1 paper) and Bone health and treatments (1 paper). The work is most often cited by research in Hematology (228 citations), Genetics (185 citations) and Rheumatology (138 citations). Matthew J. Wong has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Victor M. Rivera, Joseph M. Gozgit, Tim Clackson, Scott Wardwell, William C. Shakespeare, Narayana I. Narasimhan, Frank Wang, Qurish K. Mohemmad, Lauren Moran and Brian Druker. Their work appears in journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact